Posted by Michael Wonder on 21 Mar 2018
EMA publishes agenda for March 19-22 CHMP meeting
19 March 2018 - The EMA has published a draft agenda for this week's CHMP meeting.
The CHMP is due to issue initial opinions for the following technologies:
- Betrixaban
- Dolutegravir sodium with rilpivirine hydrochloride
- Trastuzumab
- Pemetrexed disodium heptahydrate
- Prasugrel
- Rucaparib camsylate
- Abaloparatide
- Infliximab
